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Introduction
Artificial oxygen carriers aim at improving oxygen trans-
port and oxygen unloading to the tissue. Artificial oxygen
carriers may thus be used as an alternative to allogeneic
blood transfusions or to improve tissue oxygenation and
function of organs with marginal oxygen supply. The
present article describes the currently evaluated perfluo-
rocarbon emulsions, in order to summarize their efficacy,
discuss potential side effects and illustrate potential
future applications.
Background of perfluorocarbon emulsions
Perfluorochemicals are chemically inert synthetic mole-
cules that consist primarily of carbon and fluorine atoms,
and are clear, colourless liquids. They have the ability to
physically dissolve significant quantities of many gases
including oxygen and carbon dioxide. Perfluorochemicals
are hydrophobic, and are therefore not miscible with water.
Perfluorochemicals thus have to be emulsified for intra-
venous use. With sophisticated technology, it is possible to
generate a stable perfluorocarbon emulsion with excep-
tionally small particles (median diameter <0.2mm) [1].
First-generation perfluorocarbon emulsions as well as
Russian or Chinese products have been described in a pre-
vious review [1]. Western development of second-genera-
tion perfluorocarbon emulsions has focused on linear
perfluorocarbon molecules such as perfluorooctyl bromide
(C8F17Br, also referred to as perflubron), perfluorodecyl
bromide (C10F21Br) and perfluorodichlorooctane
(C8F16Cl2) [1]. Using solely 3.6%w/v egg yolk phospho-
lipid, Alliance Pharmaceutical Corporation (San Diego,
California, USA) developed a concentrated (60%w/v) and
stable perfluorocarbon emulsion, Oxygent, which is com-
posed of 58%w/v perfluorooctyl bromide and 2%w/v per-
fluorodecyl bromide, with an average particle size of
0.16–0.18mm diameter. Hemagen/perfluorocarbon (St
Louis, Missouri, USA) developed another concentrated
(40% v/v) perfluorocarbon emulsion, Oxyfluor, using per-
fluorodichlorooctane, egg yolk phospholipid and triglyc-
erid with an average particle size of 0.22–0.25mm diameter.
After intravenous administration, the droplets of the per-
fluorocarbon emulsion are taken up by the reticuloen-
dothelial system (RES). This uptake into the RES
RES = reticuloendothelial system; ANH = acute normovolemic haemodilution.
Perfluorocarbon emulsions are being clinically evaluated as artificial oxygen
carriers to reduce allogeneic blood transfusions or to improve tissue
oxygenation. Perfluorocarbon emulsions are efficacious in animal experiments,
and in humans they are well tolerated and at least as successful to reverse
physiologic transfusion triggers than autologous blood. Perfluorocarbon
emulsions may be used in the future in the concept of augmented acute
normovolaemic haemodilution. In this concept relatively low preoperative
haemoglobin levels are targeted during preoperative normovolaemic
haemodilution and a perfluorocarbon emulsion is given to augment oxygen
delivery during surgery when low endogenous haemoglobin levels are expected.
The autologous blood is subsequently retransfused in the postoperative period
when the patient’s oxygenation is provided primarily by the endogenous
haemoglobin. Additional uses of perfluorocarbon emulsions will include
treatments of diseases with compromised tissue oxygenation such as cerebral or
myocardial ischaemia, air embolism and emergency or trauma surgery as long as
no allogeneic blood is available.
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half life is dose-dependent, and for Oxygent was found to
be 9.4±2.2h for a dose of 1.8g/kg [4]. After the initial
uptake of the perfluorocarbon emulsion into the RES the
droplets are slowly broken down, and the perfluorocarbon
molecules are taken up in the blood again (bound to blood
lipids) and transported to the lungs, where the unaltered
perfluorocarbon molecules are finally excreted via exhala-
tion. At present no metabolism of fluorocarbon molecules
is known in humans [1–3].
Safety profile
Oxygent and Oxyfluor both underwent extensive safety
testing. The results of most of these studies are not pub-
lished in the scientific literature, but they form the basis
for regulatory authorities to allow clinical testing. Common
side effects such as delayed febrile reaction and flu-like
symptoms seem to be related to the normal activity of
phagocytic cells of the RES. The magnitude of these side
effects depend on the particle size of the emulsion. Smaller
particles (0.1–0.2mm diameter) appear to be less detectable
for the RES than larger particles (>0.2mm diameter) and
cause only mild temperature increases and mild flu-like
symptoms in relatively few individuals [1,3,5].
Once in the RES, excretion depends on vapor pressure
and lipid solubility of flourocarbons. Elimination half-time
is 3–4 days for perfluorooctyl bromide and 8 days for per-
fluorodichlorooctane. Because flourocarbon molecules are
inert to biochemical degradation, they diffuse back into
the blood where they dissolve in plasma lipids. These
lipids transport the perfluorocarbon molecules to the lungs
where they are excreted by exhalation.
At higher doses (1.7g/kg Oxyfluor, 1.8g/kg Oxygent) a tran-
sient decrease in platelet count was observed 2–3 days after
dosing, with recovery by 7–14 days [1,6]. With Oxygent,
however, the decrease in platelet count was mild (10–20%)
and no drug-related effects on platelet function were
observed. Furthermore, plasmatic coagulation was not com-
promised and template bleeding time was not prolonged by
1.8g/kg Oxygent [1,6]. In addition, there was no comple-
ment activation [7]; no suppression of humoral or cell-medi-
ated immune function; no haemodynamic effects or
vasoconstriction; no changes in liver, lung or renal function;
and no clinically relevant effects on blood chemistry [1].
Oxygen transport
Oxygen transport characteristics of perfluorocarbon emul-
sions are fundamentally different from those of blood
(Fig. 1). Blood exhibits a sigmoidal oxygen dissociation
curve. In contrast, perfluorocarbon emulsions are charac-
terized by a linear relationship between oxygen partial
pressure and oxygen content. Elevated arterial oxygen
partial pressures are thus beneficial to maximize the
oxygen transport capacity of perfluorocarbon emulsions.
Ventilation with 100% oxygen may raise concerns regard-
ing oxygen toxicity. During relatively short exposure
times (<8h), however, no evidence of oxygen toxicity was
detected [8] and the earliest signs of oxygen toxicity were
observed only after 18h [9].
Red blood cells are flexible, disk-shaped cells approxi-
mately 7–8mm in diameter and are packed with highly
concentrated hemoglobin. In arterioles red cells fill most
of the vessel diameter with a relatively small plasma phase
near the vessel wall where smaller cells such as platelets
(1mm in diameter) and small particles concentrate (near-
wall particle excess phenomenon). In the capillaries the
distance between red blood cells increases, producing sig-
nificant intercellular plasma gaps, and capillaries are found
that are perfused by plasma only.
Due to the small size (<0.2mm in diameter) perfluorocar-
bon emulsion particles mainly flow in the peripheral
plasma layer in larger vessels [1,10]. In the microcircula-
tion, perfluorocarbon emulsion particles perfuse even the
tiniest capillaries (4–5mm in diameter), where no red
blood cells may flow under certain conditions. It is pre-
cisely this area in which perfluorocarbon emulsions exert
their greatest effects, because they augment local oxygen
delivery much more than would be expected from the
increase in oxygen content in the arterial blood (large
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Figure 1
Perfluorocarbon emulsion and blood-based oxygen transport: oxygen
dissociation curve of native human blood (Blood) and a
perfluorocarbon (PFC) emulsion. Note that 5 volume % (5 Vol%) of
oxygen can be offloaded by blood as well as by a PFC emulsion. With
a PFC emulsion, higher arterial partial oxygen tension values are
required. Note also that PFC emulsion-transported oxygen is more
completely offloaded than blood-transported oxygen, resulting in an
approximate oxygen extraction (O2-Ex.) ratio of 90% for the PFC
emulsion, as compared with approximately 25% for blood, assuming a
normal mixed venous partial oxygen tension of approximately
40mmHg. C O2, oxygen content; PO2, partial oxygen tension.
Modified according to Looker et al [24] and Keipert et al [11]).vessel with red blood cells) [1]. Another important aspect
that determines the efficacy of perfluorocarbon emulsions
is the fact that all oxygen carried by the perfluorocarbon is
in the dissolved state, resulting in a higher oxygen partial
pressures in the microcirculation and thereby augmenting
the driving pressure for the diffusion of dissolved oxygen
into the tissue.
Preclinical efficacy of second-generation
perfluorocarbon emulsions
A perflubron emulsion (Oxygent) was assessed in a variety
of haemodilution studies. Keipert et al [11] applied perflu-
bron emulsion in dogs after acute normovolemic haemodi-
lution (ANH) at a haematocrit of 10%. With the
application of Oxygent, cardiac output tended to increase
and a massive rise in mixed venous oxygen partial pres-
sure and mixed venous saturation was observed. The per-
centage of metabolized oxygen that originated from
endogenous haemoglobin decreased with the application
of Oxygent, indicating that the oxygen transported by
Oxygent is preferentially metabolized, due to its excellent
oxygen unloading characteristics [11].
An increase in mixed venous oxygen partial pressure indi-
cates improvement in global oxygenation status [12],
rather than shunting of oxygen from arterioles directly into
venules (i.e. oxygen bypassing the microcirculation). This
view is substantiated by a study that demonstrated an
increase of oxygen consumption in a maximally working,
in-situ gastrocnemius muscle preparation in anesthetized
and haemodiluted dogs after Oxygent administration [12].
It is also substantiated by the fact that increases in mixed
venous oxygen partial pressure are generally associated
with an Oxygent-dependent improvement in tissue oxy-
genation, as demonstrated in the heart, brain, muscle, gut
and liver [13,14]. Furthermore, Holman et al [15] tested
Oxygent in severely haemodiluted dogs undergoing car-
diopulmonary bypass. Dogs treated with increasing doses
of Oxygent survived cardiopulmonary bypass progres-
sively better than did control animals.
Oxygent may also be beneficial as an adjunct to resuscita-
tion. In a porcine model of near fatal haemorrhage,
Oxygent treatment in addition to standard resuscitation
decreased mortality from 43 to 13% [16]. Infusion of oxy-
genated Oxygent into the aortic arch also improved
outcome in another resuscitation model [17].
Mixed venous oxygen partial pressure was higher in
Oxygent-treated animals after ANH to a haemoglobin of
7g/dl than in control animals [14,18], and measures of left
ventricular systolic and diastolic contractile function were
found to be improved after Oxygent administration at a
haemoglobin level of 3g/dl [19]. This might be explained
by an augmented oxygen delivery through very narrow
capillaries where Oxygent particles may penetrate better
than the relatively large red blood cells, and thereby
improve local tissue oxygenation more than red blood cells
[1]. These studies thus indicate that Oxygent indeed
transports and unloads oxygen into the areas where it is
needed most.
Clinical efficacy of second-generation
perfluorocarbon emulsions
Oxygent has also been used in humans [6,20,21,22]. ANH
to a haemoglobin concentration of approximately 9g/dl was
performed [20]. During surgery Oxygent (0.9g/kg) was
administered when a blood transfusion was deemed neces-
sary by the anaesthesiologist, which occurred at a haemo-
globin concentration of approximately 8g/dl. Mixed venous
oxygen tension and mixed venous oxygen saturation both
increased significantly after Oxygent administration, and
cardiac output was stable. Although only relatively little
oxygen was transported by perflubron emulsion (approxi-
mately 1%), 5% of the metabolized oxygen was transported
by Oxygent, again indicating that Oxygent-transported
oxygen is preferentially metabolized [11,20].
Recently, the results of two large prospective randomized
multicenter studies on the use of Oxygent in orthopaedic
and genitourinary surgery were presented [21,22]. In the
orthopaedic study [21], 147 patients undergoing hip
replacement and spine surgery were haemodiluted preop-
eratively to a hemoglobin level of 9g/dl. After the patients
had reached a predefined transfusion trigger, they were
randomized into four groups: standard of care (retransfu-
sion of 450 ml autologous blood at an unchanged fractional
inspired oxygen of 0.4); Oxygent (0.9 or 1.8g/kg) with
colloid to a total 450ml with ventilation with an fractional
inspired oxygen of 1.0; and infusion of 450ml colloid with
ventilation with an fractional inspired oxygen of 1.0.
Oxygent (1.8g/kg) was most successful in reversing trans-
fusion triggers in 97% of patients, as compared with 60%
in the control group. The duration of transfusion trigger
reversal in the Oxygent 1.8g/kg group was significantly
longer (80min) than in the control and colloid groups (55
and 30min, respectively). In the study that including 109
patients undergoing genitourinary surgery [22], similar
results were achieved. Thus, physiologic transfusion trig-
gers may be treated at least as successfully with Oxygent
as with autologous blood of colloids. This illustrates the
remarkable potency of Oxygent to deliver readily available
oxygen to those areas in the body in which the extra
oxygen is needed most.
Future uses of perfluorocarbon emulsions
Optimal use of perfluorocarbon emulsions in the future
may consist of a combination of ANH preoperatively with
application of an artificial oxygen carrier such as a perfluo-
rocarbon emulsion during the operation, a procedure
termed ‘augmented ANHSM’ [Roth DJ, Keipert PE,
Faithfull NS, Zuck TF, Riess JG: Facilitated oxygen
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#5,451,205 (issued September 19, 1995) and European
Patent #EP 0627 913 B1 (issued April 4, 1998] (Fig. 2).
Augmented ANH is a concept in which patients undergo
ANH to relatively low haemoglobin levels preoperatively.
During the operation, when the haemoglobin concentra-
tion decreases further due to surgical blood loss and
concomitant colloid or crystalloid replacement, perfluoro-
carbon emulsions in conjunction with 100% oxygen venti-
lation is administered to enhance oxygen delivery and
improve tissue oxygenation. As a consequence, lower
levels of haemoglobin concentration can be safely toler-
ated. Towards the end of the operation, the autologous
blood harvested during ANH is retransfused. This will
result in a relatively high haemoglobin concentration in
the postoperative period and oxygen delivery will again be
provided by endogenous haemoglobin. Therefore, greatly
elevated arterial partial oxygen tension values are not nec-
essary in the postoperative period and the relatively short
half-life of perfluorocarbon emulsions (<24h) will not
compromise their success in reducing allogeneic blood
transfusion requirement (Fig. 2).
For the concept of augmented ANH, it is important not to
compromise blood coagulation during the surgical proce-
dure [1,6], otherwise blood loss might be enhanced and
thus allogeneic blood savings limited. Therefore, a careful
selection of colloids is necessary to avoid blood coagula-
tion becoming compromised [23].
Apart from the use of perfluorocarbon emulsions to reduce
allogeneic blood transfusions in surgery, there are numer-
ous other potential future indications based on their poten-
tial to augment tissue oxygenation. Such future indications
will probably include treatment and prevention of cerebral
ischaemia, stroke, cardiopulmonary bypass-related cerebral
adverse events, spinal cord ischaemia, myocardial
ischaemia due to acute infarction, percutaneous coronary
angioplasty, acute limb ischaemia, emergency surgery and
trauma as long as no allogeneic blood is available [21], and
decompression sickness. Other applications include the
use of perfluorocarbon emulsions to augment tumour oxy-
genation to render them more sensitive to radiation and
chemotherapy, to prevent or treat sequelae of air
embolism, and finally to improve organ preservation for
subsequent organ transplantation (referenced in [1]).
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